Differential biodistribution of adenoviral vector in vivo as monitored by bioluminescence imaging and quantitative polymerase chain reaction

Human Gene Therapy

Volumn 17, Issue 12, 2006, Pages 1262-1269

  Johnson, Mai ^a   Huyn, Steve ^b   Burton, Jeremy ^b   Sato, Makoto ^a   Wu, Lily ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; FIREFLY LUCIFERASE; VIRUS DNA; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AXILLARY LYMPH NODE; BIOLUMINESCENCE; BIOLUMINESCENCE IMAGING; CONTROLLED STUDY; CYTOMEGALOVIRUS; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; IMAGING SYSTEM; IN VIVO STUDY; KIDNEY; LIVER; LUNG; LYMPH NODE; LYMPHATIC DRAINAGE; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROSTATE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SHOULDER; SPLEEN; SUBCUTANEOUS TISSUE; THORAX; TREATMENT PLANNING; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS GENE; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; BASE SEQUENCE; DNA PRIMERS; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; LIVER; LUCIFERASES, FIREFLY; LUMINESCENT MEASUREMENTS; LYMPH NODES; MALE; MICE; MICE, SCID; POLYMERASE CHAIN REACTION; PROSTATE; RECOMBINANT PROTEINS; TISSUE DISTRIBUTION;

ADENOVIRIDAE; CYTOMEGALOVIRUS;

EID: 33845754406     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.17.1262     Document Type: Article

References (40)

1. ADAMS, J.Y., JOHNSON, M., SATO, M., BERGER, F., GAMBHIR, S.S., CAREY, M., IRUELA-ARISPE, M.L., and WU, L. (2002). Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nat. Med. 8, 891-897.
2. AL-DOSARI, M., ZHANG, G., KNAPP, J.E., and LIU, D. (2006). Evaluation of viral and mammalian promoters for driving transgene expression in mouse liver. Biochem. Biophys. Res. Commun. 339, 673-678.
3. ALEMANY, R., and CURIEL, D.T. (2001). CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther. 8, 1347-1353.
4. ALEMANY, R., SUZUKI, K., and CURIEL, D.T. (2000). Blood clearance rates of adenovirus type 5 in mice. J. Gen. Virol. 81, 2605-2609.
5. BERGELSON, J.M., CUNNINGHAM, J.A., DROGUETT, G., KURT-JONES, E.A., KRITHIVAS, A., HONG, J.S., HORWITZ, M.S., CROWELL, R.L., and FINBERG, R.W. (1997). Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320-1323.
6. BERGELSON, J.M., KRITHIVAS, A., CELI, L., DROGUETT, G., HORWITZ, M.S., WICKHAM, T., CROWELL, R.L., and FINBERG, R.W. (1998). The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J. Virol. 72, 415-419.
7. BERNT, K.M., NI, S., GAGGAR, A., LI, Z.Y., SHAYAKHMETOV, D.M., and LIEBER, A. (2003). The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors. Mol. Ther. 8, 746-755.
8. BOSHART, M., WEBER, F., JAHN, G., DORSCH-HASLER, K., FLECKENSTEIN, B., and SCHAFFNER, W. (1985). A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell 41, 521-530.
9. CHARTIER, C., DEGRYSE, E., GANTZER, M., DIETERLE, A., PAVIRANI, A., and MEHTALI, M. (1996). Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coll. J. Virol. 70, 4805-4810.
10. CROYLE, M.A., ROESSLER, B.J., DAVIDSON, B.L., HILFINGER, J.M., and AMIDON, G.L. (1998). Factors that influence stability of recombinant adenoviral preparations for human gene therapy. Pharm. Dev. Technol. 3, 373-383.
11. DECHECCHI, M.C., MELOTTI, P., BONIZZATO, A., SANTA-CATTERINA, M., CHILOSI, M., and CABRINI, G. (2001). Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J. Virol. 75, 8772-8780.
12. GONIN, P., and GAILLARD, C. (2004). Gene transfer vector biodistribution: Pivotal safety studies in clinical gene therapy development. Gene Ther. 11(Suppl. 1), S98-S108.
13. HERMAN, J.R., ADLER, H.L., AGUILAR-CORDOVA, E., ROJAS-MARTINEZ, A., WOO, S., TIMME, T.L., WHEELER, T.M., THOMPSON, T.C., and SCARDINO, P.T. (1999). In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial. Hum. Gene Ther. 10, 1239-1249.
14. HIGUCHI, R., DOLLINGER, G., WALSH, P.S., and GRIFFITH, R. (1992). Simultaneous amplification and detection of specific DNA sequences. Biotechnology 10, 413-417.
15. ILAGAN, R., ZHANG, L.J., POTTRATZ, J., LE, K., SALAS, S., IYER, M., WU, L., GAMBHIR, S.S., and CAREY, M. (2005). Imaging androgen receptor function during flutamide treatment in the LAPC9 xenograft model. Mol. Cancer Ther. 4, 1662-1669.
16. JOHNSON, M., SATO, M., BURTON, J., GAMBHIR, S.S., CAREY, M., and WU, L. (2005). Micro-PET/CT monitoring of herpes thymidine kinase suicide gene therapy in a prostate cancer xenograft: The advantage of a cell-specific transcriptional targeting approach. Mol. Imaging 4, 463-472.
17. KANERVA, A., WANG, M., BAUERSCHMITZ, G.J., LAM, J.T., DESMOND, R.A., BHOOLA, S.M., BARNES, M.N., ALVAREZ, R.D., SIEGAL, G.P., CURIEL, D.T., and HEMMINKI, A. (2002). Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol. Ther. 5, 695-704.
18. LEISSNER, P., LEGRAND, V., SCHLESINGER, Y., HADJI, D.A., VAN RAAIJ, M., CUSACK, S., PAVIRANI, A., and MEHTALI, M. (2001). Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism. Gene Ther. 8, 49-57.
19. LEON, R.P., HEDLUND, T., MEECH, S.J., LI, S., SCHAACK, J., HUNGER, S.P., DUKE, R.C., and DEGREGORI, J. (1998). Adenoviral-mediated gene transfer in lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 95, 13159-13164.
20. -ΔΔCT method. Methods 25, 402-408.
21. LOZIER, J.N., CSAKO, G., MONDORO, T.H., KRIZEK, D.M., METZGER, M.E., COSTELLO, R., VOSTAL, J.G., RICK, M.E., DONAHUE, R.E., and MORGAN, R.A. (2002). Toxicity of a first-generation adenoviral vector in rhesus macaques. Hum. Gene Ther. 13, 113-124.
22. MORRISON, T.B., WEIS, J.J., and WITTWER, C.T. (1998). Quantification of low-copy transcripts by continuous SYBR green I monitoring during amplification. Biotechniques 24, 954-958, 960, 962.
23. NUNES, P.A., FURTH, E.E., WILSON, J.M., and RAPER, S.E. (1999). Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: Safety of readministration. Hum. Gene Ther. 10, 2515-2526.
24. PLANTE, M.K., FOLSOM, J.B., and ZVARA, P. (2004). Prostatic tissue ablation by injection: A literature review. J. Urol. 172, 20-26.
25. SATO, M., JOHNSON, M., ZHANG, L., ZHANG, B., LE, K., GAMBHIR, S.S., CAREY, M., and WU, L. (2003). Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy. Mol. Ther. 8, 726-737.
26. SCHMIDT, E.V., CHRISTOPH, G., ZELLER, R., and LEDER, P. (1990). The cytomegalovirus enhancer: A pan-active control element in transgenic mice. Mol. Cell. Biol. 10, 4406-4411.
27. SCHMITTGEN, T.D., ZAKRAJSEK, B.A., MILLS, A.C., CORN, V., SINGER, M.J., and REED, M.W. (2000). Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: Comparison of endpoint and real-time methods. Anal. Biochem. 285, 194-204.
28. TAO, N., GAO, G.P., PARR, M., JOHNSTON, J., BARADET, T., WILSON, J.M., BARSOUM, J., and FAWELL, S.E. (2001). Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol. Ther. 3, 28-35.
29. TILNEY, N.L. (1971). Patterns of lymphatic drainage in the adult laboratory rat. J. Anat. 109, 369-383.
30. TIMME, T.L., HALL, S.J., BARRIOS, R., WOO, S.L., AGUILAR-CORDOVA, E., and THOMPSON, T.C. (1998). Local inflammatory response and vector spread after direct intraprostatic injection of a recombinant adenovirus containing the herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice. Cancer Gene Ther. 5, 74-82.
31. VRANCKEN PEETERS, M.J., PERKINS, A.L., and KAY, M.A. (1996). Method for multiple portal vein infusions in mice: Quantitation of adenovirus-mediated hepatic gene transfer. Biotechniques 20, 278-285.
32. WANG, Y., YANG, Z., LIU, S., KON, T., KROL, A., LI, C.Y., and YUAN, F. (2005). Characterisation of systemic dissemination of non-replicating adenoviral vectors from tumours in local gene delivery. Br. J. Cancer 92, 1414-1420.
33. WEISSLEDER, R. (2001). A clearer vision for in vivo imaging. Nat. Biotechnol. 19, 316-317.
34. 5 promote adenovirus internalization but not virus attachment. Cell 73, 309-319.
35. WILSON, I.M. (1996). Adenoviruses as gene-delivery vehicles. N. Engl. J. Med. 334, 1185-1187.
36. WINER, I., IUNG, C.K., SHACKEL, I., and WILLIAMS, P.M. (1999). Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal. Biochem. 270, 41-49.
37. WOOD, M., PERROTTE, P., ONISHI, E., HARPER, M.E., DINNEY, C., PAGLIARO, L., and WILSON, D.R. (1999). Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse. Cancer Gene Ther. 6, 367-372.
38. WU, L., JOHNSON, M., and SATO, M. (2003). Transcriptionally targeted gene therapy to detect and treat cancer. Trends Mol. Med. 9, 421-429.
39. ZARRIN, A.A., MALKIN, L., FONG, I., LUK, K.D., GHOSE, A., and BERINSTEIN, N.L. (1999). Comparison of CMV, RSV, SV40 viral and Vλ1 cellular promoters in B and T lymphoid and non-lymphoid cell lines. Biochim. Biophys. Acta 1446, 135-139.
40. ZHANG, L., JOHNSON, M., LE, K.H., SATO, M., ILAGAN, R., IYER, M., GAMBHIR, S.S., WU, L., and CAREY, M. (2003). Interrogating androgen receptor function in recurrent prostate cancer. Cancer Res. 63, 4552-4560.